On May 3, 2026, Candid Therapeutics announced it was terminating its previously announced merger agreement with Rallybio Corporation, a decision that was filed with the U.S. Securities and Exchange Commission the following day. The termination ends the $50 million parent termination fee that Rallybio had expected to receive upon completion of the deal.
The $50 million fee is a significant non‑operating cash inflow that brings Rallybio’s cash balance, including short‑term investments, to roughly $54.7 million. The fee offsets the loss of the merger exit and provides a financial cushion that extends the company’s runway.
Rallybio’s operating cash burn has been estimated at about $36 million per year, based on quarterly cash outflows of roughly $9 million. With the new cash balance, the company now has a runway of just over 1.5 years, assuming current burn rates remain unchanged.
Rallybio’s Phase 1‑ready RLYB116 program, a C5 inhibitor for complement‑mediated diseases, remains its flagship asset. The company will continue to evaluate alternative transactions “with the goal of maximizing value for shareholders,” while pursuing further development of RLYB116 and other pipeline candidates.
Investors reacted positively to the announcement, reflecting confidence in the $50 million termination fee and the company’s continued focus on its core science. Rallybio’s CEO, Stephen Uden, has expressed confidence in the RLYB116 data, and the company has withdrawn the registration statement that had been filed in connection with the original merger.
The original merger, announced on March 1, 2026, would have combined Rallybio with Candid under the name Candid Therapeutics and traded as CDRX, supported by more than $505 million in committed private financing. Candid’s decision to pursue an alternative transaction with UCB S.A. prompted the termination, leaving Rallybio to chart a new path forward.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.